First Trust Advisors LP Raises Holdings in Halozyme Therapeutics, Inc. $HALO

First Trust Advisors LP boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 46.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,482,340 shares of the biopharmaceutical company’s stock after acquiring an additional 470,558 shares during the period. First Trust Advisors LP’s holdings in Halozyme Therapeutics were worth $95,804,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC boosted its stake in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the last quarter. Abel Hall LLC lifted its holdings in Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 129 shares in the last quarter. StoneX Group Inc. boosted its stake in shares of Halozyme Therapeutics by 3.8% during the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 132 shares during the last quarter. Moran Wealth Management LLC grew its holdings in shares of Halozyme Therapeutics by 0.4% during the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after buying an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. grew its stake in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 161 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of Halozyme Therapeutics in a report on Tuesday. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Finally, UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Stock Up 1.3%

Shares of Halozyme Therapeutics stock opened at $81.93 on Friday. The company has a fifty day moving average price of $73.08 and a 200 day moving average price of $70.58. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a twelve month low of $57.67 and a twelve month high of $82.99. The stock has a market cap of $9.72 billion, a price-to-earnings ratio of 29.47, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue was up 42.2% compared to the same quarter last year. During the same period last year, the company posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $61,245,810.60. This represents a 0.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 74,102 shares of company stock valued at $5,205,798. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.